ExpediteBio will contribute its integrated biologics development expertise and collaborative ecosystem to accelerate oncology innovation.

 

Woubrugge, the Netherlands, July 21, 2026 – ExpediteBio is pleased to announce that it has joined the Oncode Accelerator program as an industry partner in the Biologics Workstream, contributing its expertise to accelerate the development of next-generation biologic therapies for cancer. The Oncode Accelerator program brings together leading academic institutions, healthcare organizations, and innovative companies to bridge the gap between groundbreaking cancer research and clinical application. Through close collaboration, the program aims to accelerate the translation of promising scientific discoveries into innovative therapies for patients.

 

As a partner in the Biologics Workstream, ExpediteBio will contribute its expertise in process development, optimization, and translation of biologic drug candidates for clinical use. Leveraging its integrated technology platform and streamlined development capabilities, the company will support the efficient progression of therapeutic antibodies and other protein-based medicines toward clinical development.

 

Jetta Bijlsma, Director of Program Management at Oncode Accelerator, elaborated: “Building one seamless infrastructure in the Biologics Workstream that supports antibody drug development from discovery up to GMP production will accelerate and de-risk the process. The partnership between ExpediteBio and Oncode Accelerator significantly contributes to building this infrastructure. We envision that the partnership can make an impact for drug developers, and eventually also for patients.”

 

Beyond its internal capabilities, ExpediteBio connects Oncode Accelerator partners with an established ecosystem of specialized technology providers, CROs, manufacturing partners, and scientific experts. This integrated network enables the company to rapidly assemble the expertise and infrastructure required across the biologics development value chain, offering partners a flexible and efficient route from early-stage innovation to development-ready candidates.

 

“We are proud to join the Oncode Accelerator program and contribute to its mission of advancing innovation in oncology. The future of biologics development depends on bringing together scientific excellence, translational expertise, the right infrastructure and industrial execution. Through this partnership, we look forward to helping transform promising academic discoveries into development-ready therapeutic candidates and ultimately improving outcomes for patients", said Richard van Rijnsoever, CEO of ExpediteBio.

 

“No single organization can provide every capability required to bring innovative biologics to the clinic. Our role is to connect the program with a carefully curated ecosystem of technology providers, development partners, and manufacturing experts, creating seamless access to complementary expertise across the biologics development pathway. This collaborative approach enables scientific teams to move promising innovations forward more efficiently", said Debby Vermeer, Chief Strategic Alliances at ExpediteBio.

 

Joining the Oncode Accelerator program reflects ExpediteBio's commitment to advancing biologic drug development through collaboration and innovation. By working alongside Oncode Accelerator's partners, the company aims to help overcome key development challenges and accelerate the development of novel therapies that improve outcomes for cancer patients.

 

 

About ExpediteBio B.V.

ExpediteBio is a biotechnology company based in Woubrugge, the Netherlands, dedicated to accelerating the development of biologic therapeutics through smarter, parallelized development models that reduce time, cost and risk for emerging therapeutics. By combining scientific expertise with an integrated ecosystem of technology, development, manufacturing, and strategic partners, ExpediteBio helps biotechnology companies and academic innovators efficiently translate promising biologics toward clinical development.

 

Website: https://www.expeditebio.com

 

About Oncode Accelerator

Oncode Accelerator is a public-private partnership that is partially funded by the Dutch National Growth Fund (NGF), aiming to innovate and accelerate the development of new cancer therapies by placing cancer patients at the core of preclinical therapy development. It is a collaboration between six coordinating partners: Leiden University, Leiden University Medical Center, the Netherlands Cancer Institute, Princess Máxima Center, UMC Utrecht and the Oncode Accelerator Foundation.

 

Website: https://www.oncodeaccelerator.nl

 

Media Contacts

ExpediteBio Communications

Email: info@expeditebio.com

 

Oncode Accelerator

Saskia Theunisse – de Jager (Director Marketing & Communications)

Tel: +31 6 57 82 14 78

Email: saskia.theunisse@oncodeaccelerator.nl  / PR@oncodeaccelerator.nl